Search Results
Results found for "Dr. GPCR ecosystem"
- John Streicher talks about his work on terpenes found in cannabis as these may be a novel way to ...
Read more at the source #DrGPCR #GPCR #IndustryNews
- Inversago Pharma appoints Glenn S. Vraniak as Chief Financial Officer
Read more at the source #DrGPCR #GPCR #IndustryNews
- Confo Therapeutics Doses First Subjects In Phase 1 Clinical Trial Of CFTX-1554 For The Treatment ...
– Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs pharmacokinetics of CFTX-1554 in healthy subjects (NCT05260658). " Read more at the source #DrGPCR #GPCR
- Modulation of Striatal Adenosinergic Function by HTL0041178, a Selective GPR52 Agonist
control neuropsychiatric symptoms in conditions such as schizophrenia. " Read more at the source #DrGPCR #GPCR
- Trevena Receives up to $40M in OLINVYK ex-US Royalty-Based Financing from R-Bridge Healthcare ...
Read more at the source #DrGPCR #GPCR #IndustryNews
- Trevena Announces Receipt of First $15 million Tranche in Connection with its $40 million ...
Read more at the source #DrGPCR #GPCR #IndustryNews
- Applying Allosteric Modulator Pharmacology to Treat Dyskinesia and Other Movement Disorders with ...
Read more at the source #DrGPCR #GPCR #IndustryNews
- Crinetics Pharmaceuticals Announces Pricing Of Underwritten Common Stock Offering
Read more at the source #DrGPCR #GPCR #IndustryNews
- Addex Therapeutics Completes Patient Enrollment For Dipraglurant Blepharospasm Phase 2 Clinical ...
Read more at the source #DrGPCR #GPCR #IndustryNews
- Addex Expands Pipeline With Selective M4 Positive Allosteric Modulator Program For The Treatment ...
Read more at the source #DrGPCR #GPCR #IndustryNews
- Sosei Heptares reported its FY2021 financial result and provided an update on operational activities
February 2022 Read more at the source #DrGPCR #GPCR #IndustryNews
- Crinetics Pharmaceuticals Expands Executive Team With Appointment Of James Hassard As Chief ...
Read more at the source #DrGPCR #GPCR #IndustryNews
- Inversago Pharma Announces Dosing of First Participant with Metabolic Syndrome in Phase 1B ...
Read more at the source #DrGPCR #GPCR #IndustryNews
- Sosei Heptares Enters Antibody Discovery Agreement with Twist Bioscience to Discover and Develop ...
Discovery Agreement with Twist Bioscience to Discover and Develop Novel Therapeutic Antibodies against GPCR world-leading StaR® (stabilized receptor) platform to generate novel antibody leads to disease-relevant GPCR Cambridge, UK, 16 December 2021 – Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in GPCR-focused announced a strategic collaboration to discover therapeutic antibodies against G protein-coupled receptors (GPCR Read more at the source #DrGPCR #GPCR #IndustryNews
- Orion Announces The Rapid Lead Optimization Of Ob-004 - A Ccr2 Antagonist
Biotechnology, a clinical stage company unlocking the therapeutic potential of G Protein-Coupled Receptors (GPCRs OB-004 is a GPCR targeted protein analog of CCL2 that targets the CCR2 receptor. Read more at the source #DrGPCR #GPCR #IndustryNews
- VIB spin-off Confo Therapeutics Enters Collaborative Agreement with Regeneron
December 2021 "30/11/2021 Confo will work together with Regeneron to apply its GPCR drug discovery platform technology platform, which uses conformationally selective VHH antibodies – ConfoBodies® – to stabilize GPCRs enabling the discovery of novel therapeutic antibody drug candidates. " Read more at the source #DrGPCR #GPCR
- How Fast Does a Drug Work?
Dr. s Corner  ______ #DrugDiscovery #Pharmacology #DrugKinetics #PipelineEfficiency #PharmaInnovation #GPCR
- ShouTi Pharma has a brand new website
Read more at the source #DrGPCR #GPCR #IndustryNews
- Learn more about Neurocrine Biosciences with their new video
Read more at the source #DrGPCR #GPCR #IndustryNews
- Orthosteric vs. Allosteric Interactions: The Silent Decider of Safety and Success
Dr. Kenakin walks through this as a living system , showing how GPCRs exist in multiple conformations and stay ahead of the science 🧠Content built for biotech, pharma & academia 💬 Live monthly AMA with Dr Kenakin   💎 $2999/year — one conference cost = 12 months of expert training  Premium Dr. GPCR members save  50%+  (check your Weekly News code).
- Trevena Announce Submission of New Drug Application in China for OLINVYK® by its Partner Jiangsu ...
Read more at the source #DrGPCR #GPCR #IndustryNews
- Finding needles in haystacks: Omass unveils pipeline aimed at tough-to-drug targets
The targets, including G protein-coupled receptors (GPCRs), intracellular protein complexes and solute Read more at the source #DrGPCR #GPCR #IndustryNews
- Newly launched antibody libraries put hard-to-drug targets within reach
To target hard-to-drug targets like G protein-coupled receptors (GPCRs), more libraries, including better Read more at the source #DrGPCR #GPCR #IndustryNews
- Perkins’ Head of Molecular Endocrinology and Pharmacology, Professor Kevin Pfleger, was appointed...
Read more at the source #DrGPCR #GPCR #IndustryNews
- First in Human: Early-stage COVID therapies hold promise against omicron variant
Read more at the source #DrGPCR #GPCR #IndustryNews
- Novel interaction between neurotrophic factor-α1/carboxypeptidase E and serotonin receptor, 5-HTR1E,
"Protecting neurons from death during oxidative and neuroexcitotoxic stress is key for preventing cognitive dysfunction. We uncovered a novel neuroprotective mechanism involving interaction between neurotrophic factor-α1 (NF-α1/carboxypeptidase E, CPE) and human 5-HTR1E, a G protein-coupled serotonin receptor with no previously known neurological function. Co-immunoprecipitation and pull-down assays confirmed interaction between NFα1/CPE and 5-HTR1E and 125I NF-α1/CPE-binding studies demonstrated saturable, high-affinity binding to 5-HTR1E in stably transfected HEK293 cells (Kd = 13.82 nM). Treatment of 5-HTR1E stable cells with NF-α1/CPE increased pERK 1/2 and pCREB levels which prevented a decrease in pro-survival protein, BCL2, during H2O2-induced oxidative stress. Cell survival assay in β-arrestin Knockout HEK293 cells showed that the NF-α1/CPE-5-HTR1E-mediated protection against oxidative stress was β-arrestin-dependent. Molecular dynamics studies revealed that NF-α1/CPE interacts with 5-HTR1E via 3 salt bridges, stabilized by several hydrogen bonds, independent of the serotonin pocket. Furthermore, after phosphorylating the C-terminal tail and intracellular loop 3 (ICL3) of NF-α1/CPE-5-HTR1E, it recruited β-arrestin1 by forming numerous salt bridges and hydrogen bonds to ICL2 and ICL3, leading to activation of β-arrestin1. Immunofluorescence studies showed 5-HTR1E and NF-α1/CPE are highly expressed and co-localized on cell surface of human hippocampal neurons. Importantly, knock-down of 5-HTR1E in human primary neurons diminished the NF-α1/CPE-mediated protection of these neurons against oxidative stress and glutamate neurotoxicity-induced cell death. Thus, NF-α1/CPE uniquely interacts with serotonin receptor 5-HTR1E to activate the β-arrestin/ERK/CREB/BCL2 pathway to mediate stress-induced neuroprotection." Read full article
- Crinetics Pharmaceuticals announced the formation of an independently operated new company...
Read more at the source #DrGPCR #GPCR #IndustryNews
- Trevena Adds Seasoned Biopharma Commercial Executive to Senior Leadership Team
Read more at the source #DrGPCR #GPCR #IndustryNews
- Search for safer pain relief advances with new engineered compounds
Read more at the source #DrGPCR #GPCR #IndustryNews
- Decoding Schild Analysis: The Pharmacologist’s Lens on Competitive Antagonism
In the full lecture, Dr. Linearity  of the Schild regression (log(DR–1) vs. antagonist concentration). As Dr. Watch the course trailer 👇 Why Terry’s Corner Weekly pharmacology lectures by Dr. GPCR innovation is accelerating—those who act now will define tomorrow’s breakthroughs.
